Ovarian Cancer

A roundup of the latest news and updates for patients with ovarian cancer from CURE®.
 

Although the study failed to meet its goal of progression-free survival, overall survival data are currently not yet available, and follow-up will continue until the next planned analysis.
 

Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.
 

A recent data analysis found that most women diagnosed with ovarian cancer (92%) experienced abdominal and pelvic-related symptoms and visited a physician with this complaint anywhere from six to 70 months prior to diagnosis.
 

Dr. Jubilee Brown discussed the use of telemedicine and oral treatment options for patients with ovarian cancer, as well as offered advice to ease stress and anxiety throughout the COVID-19 pandemic.
 

The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.
 

The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.
 

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.
 

In this episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor - who is currently living with ovarian cancer - about a cross-country journey she took last summer on a teal and white Harley Davidson motorcycle to raise ovarian cancer awareness.